Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Bladder-Sparing treatment shows promise for avoiding surgery

NCT ID NCT02621151

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 25 times

Summary

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation can help people with muscle-invasive bladder cancer keep their bladder. About 60 participants who cannot or choose not to have bladder removal surgery will receive this combination. The main goal is to see if the cancer stays away for at least two years without needing a cystectomy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE UROTHELIAL CANCER OF THE BLADDER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Memorial Sloan Kettering

    New York, New York, 10065, United States

  • NYU Perlmutter Cancer Center

    New York, New York, 10016, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • University of Michigan Health System

    Ann Arbor, Michigan, 48109, United States

  • University of North Carolina

    Chapel Hill, North Carolina, 27599-7305, United States

Conditions

Explore the condition pages connected to this study.